SCHEMBL4661392

SCHEMBL4661392

CC(C)c1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 6/20 0.67
LMNA P02545 5/20 0.64
KDM4E B2RXH2 4/20 0.64
ADRB2 P07550 2/20 0.53
ADRB1 P08588 2/20 0.53
ADRB3 P13945 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
GLA P06280 1/20 0.51
BLM P54132 1/20 0.51
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KEAP1 Q14145 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
PGR P06401 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL301661 0.94 LMNA (0.70) KIF11LMNAKDM4EADRB2ADRB1
SCHEMBL31041151 0.85 KIF11 (0.79) KIF11LMNAKDM4EALDH1A1HPGD
Lithium SCHEMBL31041154 0.83 KIF11 (0.76) KIF11LMNAKDM4EALDH1A1HPGD
SCHEMBL21180002 0.83 KIF11 (0.62) KIF11LMNAALDH1A1HPGDHTT
SCHEMBL13524607 0.83 RXRA (0.53) KIF11LMNAKDM4EKEAP1
SCHEMBL28084837 0.81 LMNA (0.49) KIF11LMNAKDM4EADRB2ADRB1
SCHEMBL4661119 0.80 KIF11 (1.00) KIF11LMNAKDM4EALDH1A1HPGD
SCHEMBL2497654 0.80 KIF11 (0.66) KIF11LMNAKDM4EALDH1A1HPGD
SCHEMBL2002046 0.78 CA12 (0.55) KIF11LMNAKDM4EADRB2ADRB1
SCHEMBL8486918 0.78 LMNA (0.63) KIF11LMNAKDM4EADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1694281-A4 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2008-12-24 EP claimed
US-20070259951-A1 Compounds, Compositions and Methods SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 US claimed
EP-1694281-A2 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2006-08-30 EP claimed
WO-2005060692-A2 BIPHENYL COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-07 WO claimed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20070259951-A1 Compounds, Compositions and Methods SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259951-A1 Compounds, Compositions and Methods ALPP, PCNA, MKI67 KIF11 824/4885LMNA 568/4885KDM4E 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.